Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRB191
- Development stage
- Phase 1
- Lead developer
- Novartis
- Administration
- Subcutaneous
01
Overview
TRB191 is an investigational therapeutic candidate developed by Novartis for the treatment of extensive-stage small cell lung cancer (ES-SCLC). It is currently being evaluated in a Phase 1, multicenter, open-label clinical trial (CTRB191A12101) in patients whose disease has progressed after one or more prior chemotherapy regimens. The drug is administered subcutaneously, utilizing a step-up dosing schedule that begins with a priming dose on Cycle 1 Day 1, target dosing on Days 8 and 15 of Cycle 1, and subsequent maintenance dosing every 2 weeks from Cycle 2 onward.
Beyond the preview
Go deeper on TRB191.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRB191.